Non-Apoptotic Cell Death Signaling Pathways in Melanoma

by Mariusz L. Hartman
Published 2020-04-01

BH3 mimetics as a strategy to complement anticancer therapies

by Mariusz Ł. Hartman, Małgorzata Czyż
Published 2012-02-01

BRAF mutation in progression and therapy of melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma

by Izabela Zaleśna, Mariusz L. Hartman, Małgorzata Czyż
Published 2016-05-01

Physiologically Relevant Oxygen Concentration (6% O₂) as an Important Component of the Microenvironment Impacting Melanoma Phenotype and Melanoma Response to Targeted Th...

by Marta Osrodek, Mariusz L. Hartman, Malgorzata Czyz
Published 2019-08-01

MCL-1, BCL-XL and MITF Are Diversely Employed in Adaptive Response of Melanoma Cells to Changes in Microenvironment.

by Mariusz L Hartman, Beata Talar, Anna Gajos-Michniewicz, Malgorzata Czyz
Published 2015-01-01

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity

by Mariusz L. Hartman, Malgorzata Sztiller-Sikorska, Anna Gajos-Michniewicz, Malgorzata Czyz
Published 2020-01-01

17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines

by Mariusz L. Hartman, Magdalena Rogut, Aleksandra Mielczarek-Lewandowska, Michal Wozniak, Malgorzata Czyz
Published 2020-05-01

Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program

by Malgorzata Czyz, Malgorzata Sztiller-Sikorska, Anna Gajos-Michniewicz, Marta Osrodek, Mariusz L. Hartman
Published 2019-01-01

Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma ph...

by Mariusz L Hartman, Beata Talar, Muhammad Zaeem Noman, Anna Gajos-Michniewicz, Salem Chouaib, Malgorzata Czyz
Published 2014-01-01

Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro.

by Izabela Zalesna, Marta Osrodek, Mariusz L Hartman, Michal Rozanski, Malgorzata Sztiller-Sikorska, Karolina Niewinna, Dariusz Nejc, Malgorzata Czyz
Published 2017-01-01